LDLR and hyperlipidemia: British Columbia FH and Familial Combined Hyperlipidemia cohort; 391 FH patients vs. 245 non-FH patients: 28.7 (10.3–75.4) vs. 13 (10–48.9) mg/dL, p < 0.01. No significant differences were noted between carriers of a pathogenic variant in the LDLR or apolipoprotein B and noncarriers (1.43 log mg/dL vs. 1.42 log mg/dL, p = 0.97).UK Biobank cohort (n = 37,486); 221 patients with FH mutation vs. 37,265 without FH mutation: 10.7 (4.9–26.3) vs. 8.7 (4.0–25.8) mg/dL, p = 0.24.